Browse > Article
http://dx.doi.org/10.5483/BMBRep.2011.44.10.619

BMPs and their clinical potentials  

Kim, Mee-Jung (Joint Center for Biosciences at Lee Gil Ya Cancer and Diabetes Research Institute, Gachon University of Medicine and Science)
Choe, Senyon (Joint Center for Biosciences at Lee Gil Ya Cancer and Diabetes Research Institute, Gachon University of Medicine and Science)
Publication Information
BMB Reports / v.44, no.10, 2011 , pp. 619-634 More about this Journal
Abstract
Bone morphogenetic protein (BMP) signaling in diseases is the subject of an overwhelming array of studies. BMPs are excellent targets for treatment of various clinical disorders. Several BMPs have already been shown to be clinically beneficial in the treatment of a variety of conditions, including BMP-2 and BMP-7 that have been approved for clinical application in nonunion bone fractures and spinal fusions. With the use of BMPs increasingly accepted in spinal fusion surgeries, other therapeutic approaches targeting BMP signaling are emerging beyond applications to skeletal disorders. These approaches can further utilize next-generation therapeutic tools such as engineered BMPs and ex vivo-conditioned cell therapies. In this review, we focused to provide insights into such clinical potentials of BMPs in metabolic and vascular diseases, and in cancer.
Keywords
BMP; Cancer; Diabetes; Obesity; Pulmonary hypertension; TGF-beta;
Citations & Related Records

Times Cited By Web Of Science : 5  (Related Records In Web of Science)
Times Cited By SCOPUS : 1
연도 인용수 순위
  • Reference
1 Uludag, H., Friess, W., Williams, D., Porter, T., Timony, G., D'Augusta, D., Blake, C., Palmer, R., Biron, B. and Wozney, J. (1999) rhBMP-collagen sponges as osteoinductive devices: effects of in vitro sponge characteristics and protein pI on in vivo rhBMP pharmacokinetics. Ann. N. Y. Acad. Sci. 875, 369-378.   DOI
2 Kempen, D. H., Lu, L., Hefferan, T. E., Creemers, L. B., Maran, A., Classic, K. L., Dhert, W. J. and Yaszemski, M. J. (2008) Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials. 29, 3245-3252.   DOI   ScienceOn
3 Zambaux, M. F., Bonneaux, F., Gref, R., Maincent, P., Dellacherie, E., Alonso, M. J., Labrude, P. and Vigneron, C. (1998) Influence of experimental parameters on the characteristics of poly (lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Release. 50, 31-40.   DOI   ScienceOn
4 Franceschi, R. T. (2005) Biological approaches to bone regeneration by gene therapy. J. Dent. Res. 84, 1093-1103.   DOI   ScienceOn
5 Li, H. Y., Neill, H., Innocent, R., Seville, P., Williamson, I. and Birchall, J. C. (2003) Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J. Drug. Target. 11, 425-432.   DOI   ScienceOn
6 Nakashima, M. and Reddi, A. H. (2003) The application of bone morphogenetic proteins to dental tissue engineering. Nat. Biotechnol. 21, 1025-1032.   DOI   ScienceOn
7 Seeherman, H. and Wozney, J. M. (2005) Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine. Growth. Factor. Rev. 16, 329-345.   DOI   ScienceOn
8 Sabba, C., Pasculli, G., Lenato, G. M., Suppressa, P., Lastella, P., Memeo, M., Dicuonzo, F. and Guant, G. (2007) Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J. Thromb. Haemost. 5, 1149-1157.   DOI   ScienceOn
9 Oh, S. P., Seki, T., Goss, K. A., Imamura, T., Yi, Y., Donahoe, P. K., Li, L., Miyazono, K., ten Dijke, P., Kim, S. and Li, E. (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 97, 2626-2631.   DOI
10 Urness, L. D., Sorensen, L. K. and Li, D. Y. (2000) Arteriovenous malformations in mice lacking activin receptor- like kinase-1. Nat. Genet. 26, 328-331.   DOI   ScienceOn
11 Roman, B. L., Pham, V. N., Lawson, N. D., Kulik, M., Childs, S., Lekven, A. C., Garrity, D. M., Moon, R. T., Fishman, M. C., Lechleider, R. J. and Weinstein, B. M. (2002) Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development 129, 3009-3019.
12 Li, D. Y., Sorensen, L. K., Brooke, B. S., Urness, L. D., Davis, E. C., Taylor, D. G., Boak, B. B. and Wendel, D. P. (1999) Defective angiogenesis in mice lacking endoglin. Science 284, 1534-1537.   DOI   ScienceOn
13 Liu, D., Wang, J., Kinzel, B., Mueller, M., Mao, X., Valdez, R., Liu, Y. and Li, E. (2007) Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood 110, 1502-1510.   DOI   ScienceOn
14 Hruska, K. A., Guo, G., Wozniak, M., Martin, D., Miller, S., Liapis, H., Loveday, K., Klahr, S., Sampath, T. K. and Morrissey, J. (2000) Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am. J. Physiol. Renal. Physiol. 279, F130-143.   DOI
15 Gottfried, O. N. and Dailey, A. T. (2008) Mesenchymal stem cell and gene therapies for spinal fusion. Neurosurgery 63, 380-391.   DOI   ScienceOn
16 Bessa, P. C., Casal, M. and Reis, R. L. (2008) Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J. Tissue. Eng. Regen. Med. 2, 1-13.   DOI   ScienceOn
17 Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., Hewick, R. M. and Wang, E. A. (1988) Novel regulators of bone formation: molecular clones and activities. Science 242, 1528-1534.   DOI
18 Schmidmaier, G., Schwabe, P., Strobel, C. and Wildemann, B. (2008) Carrier systems and application of growth factors in orthopaedics. Injury 39(Suppl 2), S37-43.
19 Alaoui-Ismaili, M. H. and Falb, D. (2009) Design of second generation therapeutic recombinant bone morphogenetic proteins. Cytokine. Growth. Factor. Rev. 20, 501-507.   DOI   ScienceOn
20 Allendorph, G. P., Read, J. D., Kawakami, Y., Kelber, J. A., Isaacs, M. J. and Choe, S. (2011) Designer TGF-beta superfamily ligands with diversified functionality. PLoS One., In press.
21 Saito, A., Suzuki, Y., Ogata, S., Ohtsuki, C. and Tanihara, M. (2003) Activation of osteo-progenitor cells by a novel synthetic peptide derived from the bone morphogenetic protein-2 knuckle epitope. Biochim. Biophys. Acta. 1651, 60-67.   DOI   ScienceOn
22 Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., Mackey, H. M., Lum, B. L., Darbonne, W. C., Marsters, J. C. Jr., de Sauvage, F. J. and Low, J. A. (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164-1172.   DOI   ScienceOn
23 Davies, M. R., Lund, R. J. and Hruska, K. A. (2003) BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J. Am. Soc. Nephrol. 14, 1559-1567.   DOI   ScienceOn
24 Vukicevic, S., Basic, V., Rogic, D., Basic, N., Shih, M. S., Shepard, A., Jin, D., Dattatreyamurty, B., Jones, W., Dorai, H., Ryan, S., Griffiths, D., Maliakal, J., Jelic, M., Pastorcic, M., Stavljenic, A. and Sampath, T. K. (1998) Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J. Clin. Invest. 102, 202-214.   DOI   ScienceOn
25 Simic, P. and Vukicevic, S. (2005) Bone morphogenetic proteins in development and homeostasis of kidney. Cytokine. Growth. Factor. Rev. 16, 299-308.   DOI   ScienceOn
26 Zeisberg, M., Hanai, J., Sugimoto, H., Mammoto, T., Charytan, D., Strutz, F. and Kalluri, R. (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964-968.   DOI   ScienceOn
27 Li, T., Surendran, K., Zawaideh, M. A., Mathew, S. and Hruska, K. A. (2004) Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr. Opin. Nephrol. Hypertens. 13, 417-422.   DOI   ScienceOn
28 McAllister, K. A., Grogg, K. M., Johnson, D. W., Gallione, C. J., Baldwin, M. A., Jackson, C. E., Helmbold, E. A., Markel, D. S., McKinnon, W. C., Murrell, J. McCormick, M. K., Pericak-Vance, M. A., Heutink, P., Oostra, B. A., Haitjema, T., Westerman, C. J. J., Porteous, M. E., Guttmacher, A. E., Letarte, M. and Marchuk, D. A. (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 8, 345-351.   DOI   ScienceOn
29 Cheng, S. L., Shao, J. S., Charlton-Kachigian, N., Loewy, A. P. and Towler, D. A. (2003) MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J. Biol. Chem. 278, 45969-45977.   DOI   ScienceOn
30 Yu, P. B., Hong, C. C., Sachidanandan, C., Babitt, J. L., Deng, D. Y., Hoyng, S. A., Lin, H. Y., Bloch, K. D. and Peterson, R. T. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4, 33-41.   DOI   ScienceOn
31 Jiang, W. G., Martin, T. A., Lewis-Russell, J. M., Douglas- Jones, A., Ye, L. and Mansel, R. E. (2008) Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol. Cancer 7, 71.
32 Ye, L., Kynaston, H. and Jiang, W. G. (2008) Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol. Cancer Res. 6, 1594-1606.   DOI   ScienceOn
33 Ong, K. L., Villarraga, M. L., Lau, E., Carreon, L. Y., Kurtz, S. M. and Glassman, S. D. (2010) Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976). 35, 1794-1800.   DOI   ScienceOn
34 Thawani, J. P., Wang, A. C., Than, K. D., Lin, C. Y., La Marca, F. and Park, P. (2010) Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 66, 233-246.   DOI
35 Poynton, A. R. and Lane, J. M. (2002) Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine (Phila Pa 1976). 27, S40-48.   DOI   ScienceOn
36 Sundaresan, N., Boriani, S., Rothman, A. and Holtzman, R. (2004) Tumors of the osseous spine. J. Neurooncol. 69, 273-290.   DOI
37 Benglis, D., Wang, M. Y. and Levi, A. D. (2008) A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery 62, ONS-423-431.
38 Blanco Calvo, M., Bolos Fernandez, V., Medina Villaamil, V., Aparicio Gallego, G., Diaz Prado, S. and Grande Pulido, E. (2009) Biology of BMP signalling and cancer. Clin. Transl. Oncol. 11, 126-137.   DOI
39 Zebboudj, A. F., Imura, M. and Bostrom, K. (2002) Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J. Biol. Chem. 277, 4388-4394.   DOI   ScienceOn
40 Tobin, M. J. (2003) Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2002. Am. J. Respir. Crit. Care. Med. 167, 356-370.   DOI   ScienceOn
41 Yao, Y., Zebboudj, A. F., Shao, E., Perez, M. and Bostrom, K. (2006) Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1. J. Biol. Chem. 281, 33921- 33930.   DOI   ScienceOn
42 Dhore, C. R., Cleutjens, J. P., Lutgens, E., Cleutjens, K. B., Geusens, P. P., Kitslaar, P. J., Tordoir, J. H., Spronk, H. M., Vermeer, C. and Daemen, M. J. (2001) Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 21, 1998-2003.   DOI   ScienceOn
43 Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R. and Karsenty, G. (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386, 78-81.   DOI   ScienceOn
44 Sweatt, A., Sane, D. C., Hutson, S. M. and Wallin, R. (2003) Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J. Thromb. Haemost. 1, 178-185.   DOI   ScienceOn
45 Hur, D. J., Raymond, G. V., Kahler, S. G., Riegert- Johnson, D. L., Cohen, B. A. and Boyadjiev, S. A. (2005) A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. Am. J. Med. Genet. A. 135, 36-40.
46 Zhang, M. and Rosen, J. M. (2006) Stem cells in the etiology and treatment of cancer. Curr. Opin. Genet. Dev. 16, 60-64.   DOI   ScienceOn
47 Qiao, B., Johnson, N. W., Chen, X., Li, R., Tao, Q. and Gao, J. (2011) Disclosure of a stem cell phenotype in an oral squamous cell carcinoma cell line induced by BMP-4 via an epithelial-mesenchymal transition. Oncol. Rep. 26, 455-461.
48 Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., Campbell, L. L., Polyak, K., Brisken, C., Yang, J. and Weinberg, R. A. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.   DOI   ScienceOn
49 Carlson, M. E. and Conboy, I. M. (2007) Regulating the Notch pathway in embryonic, adult and old stem cells. Curr. Opin. Pharmacol. 7, 303-309.   DOI   ScienceOn
50 Katoh, M. (2011) Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr. Pharm. Biotechnol. 12, 160-170.   DOI   ScienceOn
51 Katoh, M. (2007) Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem. Cell. Rev. 3, 30-38.   DOI   ScienceOn
52 Lombardo, Y., Scopelliti, A., Cammareri, P., Todaro, M., Iovino, F., Ricci-Vitiani, L., Gulotta, G., Dieli, F., de Maria, R. and Stassi, G. (2011) Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140, 297-309.   DOI   ScienceOn
53 Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., Marshall, D., Fu, L., Januario, T., Kallop, D., Nannini-Pepe, M., Kotkow, K., Marsters, J. C., Rubin, L. L. and de Sauvage, F. J. (2008) A paracrine requirement for hedgehog signalling in cancer. Nature 455, 406-410.   DOI   ScienceOn
54 Chen, N. X. and Moe, S. M. (2003) Arterial calcification in diabetes. Curr. Diab. Rep. 3, 28-32.   DOI   ScienceOn
55 Chen, C., Grzegorzewski, K. J., Barash, S., Zhao, Q., Schneider, H., Wang, Q., Singh, M., Pukac, L., Bell, A. C., Duan, R., Coleman, T., Duttaroy, A., Cheng, S., Hirsch, J., Zhang, L., Lazard, Y., Fischer, C., Barber, M. C., Ma, Z. D., Zhang, Y. Q., Reavey, P., Zhong, L., Teng, B., Sanyal, I., Ruben, S. M., Blondel, O. and Birse, C. E. (2003) An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat. Biotechnol. 21, 294-301.   DOI   ScienceOn
56 Wang, J., Greene, S. B. and Martin, J. F. (2011) BMP signaling in congenital heart disease: new developments and future directions. Birth. Defects. Res. A. Clin. Mol. Teratol. 91, 441-448.   DOI   ScienceOn
57 Lowery, J. W. and de Caestecker, M. P. (2010) BMP signaling in vascular development and disease. Cytokine Growth Factor Rev. 21, 287-298.   DOI   ScienceOn
58 Liu, Y. and Shanahan, C. M. (2011) Signalling pathways and vascular calcification. Front. Biosci. 16, 1302-1314.   DOI
59 Rennenberg, R. J., Schurgers, L. J., Kroon, A. A. and Stehouwer, C. D. (2010) Arterial calcifications. J. Cell. Mol. Med. 14, 2203-2210.   DOI   ScienceOn
60 Corriere, M. A., Rogers, C. M., Eliason, J. L., Faulk, J., Kume, T., Hogan, B. L. and Guzman, R. J. (2008) Endothelial Bmp4 is induced during arterial remodeling: effects on smooth muscle cell migration and proliferation. J. Surg. Res. 145, 142-149.   DOI   ScienceOn
61 Bostrom, K., Watson, K. E., Horn, S., Wortham, C., Herman, I. M. and Demer, L. L. (1993) Bone morphogenetic protein expression in human atherosclerotic lesions. J. Clin. Invest. 91, 1800-1809.   DOI   ScienceOn
62 Graham, T. R., Agrawal, K. C. and Abdel-Mageed, A. B. (2010) Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells. Cancer Sci. 101, 103-111.   DOI   ScienceOn
63 Mastro, A. M., Gay, C. V. and Welch, D. R. (2003) The skeleton as a unique environment for breast cancer cells. Clin. Exp. Metastasis. 20, 275-284.   DOI
64 Schneider, A., Kalikin, L. M., Mattos, A. C., Keller, E. T., Allen, M. J., Pienta, K. J. and McCauley, L. K. (2005) Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146, 1727-1736.   DOI   ScienceOn
65 Senta, H., Park, H., Bergeron, E., Drevelle, O., Fong, D., Leblanc, E., Cabana, F., Roux, S., Grenier, G. and Faucheux, N. (2009) Cell responses to bone morphogenetic proteins and peptides derived from them: biomedical applications and limitations. Cytokine. Growth. Factor. Rev. 20, 213-222.   DOI   ScienceOn
66 Rucci, N. and Teti, A. (2010) Osteomimicry: how tumor cells try to deceive the bone. Front. Biosci (Elite Ed). 2, 907-915.
67 Bailey, J. M., Singh, P. K. and Hollingsworth, M. A. (2007) Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J. Cell. Biochem. 102, 829-839.   DOI   ScienceOn
68 Kalluri, R. and Zeisberg, M. (2006) Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401.   DOI   ScienceOn
69 Cooper, C. R., Chay, C. H., Gendernalik, J. D., Lee, H. L., Bhatia, J., Taichman, R. S., McCauley, L. K., Keller, E. T. and Pienta, K. J. (2003) Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97, 739-747.   DOI   ScienceOn
70 Sorescu, G. P., Sykes, M., Weiss, D., Platt, M. O., Saha, A., Hwang, J., Boyd, N., Boo, Y. C., Vega, J. D., Taylor, W. R. and Jo, H. (2003) Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J. Biol. Chem. 278, 31128-31135.   DOI   ScienceOn
71 Tobin, J. F. and Celeste, A. J. (2006) Bone morphogenetic proteins and growth differentiation factors as drug targets in cardiovascular and metabolic disease. Drug. Discov Today 11, 405-411.   DOI   ScienceOn
72 Miller, A. F., Harvey, S. A., Thies, R. S. and Olson, M. S. (2000) Bone morphogenetic protein-9. An autocrine/ paracrine cytokine in the liver. J. Biol. Chem. 275, 17937-17945.   DOI   ScienceOn
73 Caperuto, L. C., Anhe, G. F., Cambiaghi, T. D., Akamine, E. H., do Carmo Buonfiglio, D., Cipolla-Neto, J., Curi, R. and Bordin, S. (2008) Modulation of bone morphogenetic protein-9 expression and processing by insulin, glucose, and glucocorticoids: possible candidate for hepatic insulin-sensitizing substance. Endocrinology 149, 6326-6335.   DOI   ScienceOn
74 Lautt, W. W. (1999) The HISS story overview: a novel hepatic neurohumoral regulation of peripheral insulin sensitivity in health and diabetes. Can. J. Physiol. Pharmacol. 77, 553-562.   DOI   ScienceOn
75 Bidart, M., Ricard, N., Levet, S., Samson, M., Mallet, C., David, L., Subileau, M., Tillet, E., Feige, J. J. and Bailly, S. (2011) BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell. Mol. Life. Sci. June 28. [Epub ahead of print].
76 Anhe, F. F., Lellis-Santos, C., Leite, A. R., Hirabara, S. M., Boschero, A. C., Curi, R., Anhe, G. F. and Bordin, S. (2010) Smad5 regulates Akt2 expression and insulin- induced glucose uptake in L6 myotubes. Mol. Cell. Endocrinol. 319, 30-38.   DOI   ScienceOn
77 Galasko, C. S. (1986) Skeletal metastases. Clin. Orthop. Relat. Res. 210, 18-30.
78 Spradling, A., Drummond-Barbosa, D. and Kai, T. (2001) Stem cells find their niche. Nature 414, 98-104.   DOI   ScienceOn
79 Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M. J. (2009) Cancer statistics, 2009. CA. Cancer. J. Clin. 59, 225-249.   DOI   ScienceOn
80 Coleman, R. E. (1997) Skeletal complications of malignancy. Cancer 80, 1588-1594.   DOI   ScienceOn
81 Bussard, K. M., Gay, C. V. and Mastro, A. M. (2008) The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis. Rev. 27, 41-55.   DOI
82 Davies, S. R., Watkins, G., Douglas-Jones, A., Mansel, R. E. and Jiang, W. G. (2008) Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical/prognostic relevance. J. Exp. Ther. Oncol. 7, 327-338.
83 McMurtry, I. F. (2002) Introduction: pre- and postnatal lung development, maturation, and plasticity. Am. J. Physiol. Lung. Cell. Mol. Physiol. 282, L341-344.   DOI
84 Mundy, G. R. (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593.   DOI   ScienceOn
85 Ye, L., Mason, M. D. and Jiang, W. G. (2011) Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Front Biosci. 16, 865-897.   DOI
86 Roodman, G. D. (2004) Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664.   DOI   ScienceOn
87 Lu, X. and Kang, Y. (2010) Epidermal growth factor signalling and bone metastasis. Br. J. Cancer 102, 457-461.   DOI   ScienceOn
88 Virtanen, K. A., Lidell, M. E., Orava, J., Heglind, M., Westergren, R., Niemi, T., Taittonen, M., Laine, J., Savisto, N. J., Enerback, S. and Nuutila, P. (2009) Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360, 1518-1525.   DOI   ScienceOn
89 Song, J. J., Celeste, A. J., Kong, F. M., Jirtle, R. L., Rosen, V. and Thies, R. S. (1995) Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation. Endocrinology 136, 4293-4297.   DOI   ScienceOn
90 Cypess, A. M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A. B., Kuo, F. C., Palmer, E. L., Tseng, Y. H., Doria, A., Kolodny, G. M. and Kahn, C. R. (2009) Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509-1517.   DOI   ScienceOn
91 Saito, M., Okamatsu-Ogura, Y., Matsushita, M., Watanabe, K., Yoneshiro, T., Nio-Kobayashi, J., Iwanaga, T., Miyagawa, M., Kameya, T., Nakada, K., Kawai, Y. and Tsujisaki, M. (2009) High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58, 1526-1531.   DOI   ScienceOn
92 Zingaretti, M. C., Crosta, F., Vitali, A., Guerrieri, M., Frontini, A., Cannon, B., Nedergaard, J. and Cinti, S. (2009) The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB. J. 23, 3113-3120.   DOI   ScienceOn
93 Harris, M. I. (1998) Diabetes in America: epidemiology and scope of the problem. Diabetes Care. 21(Suppl 3), C11-14.   DOI
94 Taylor, S. I. (1999) Deconstructing type 2 diabetes. Cell 97, 9-12.   DOI   ScienceOn
95 Saltiel, A. R. (2001) New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104, 517-529.   DOI   ScienceOn
96 Clement, J. H., Raida, M., Sanger, J., Bicknell, R., Liu, J., Naumann, A., Geyer, A., Waldau, A., Hortschansky, P., Schmidt, A., Hoffken, K., Wolft, S. and Harris, A. L. (2005) Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int. J. Oncol. 27, 401-407.
97 Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordon-Cardo, C., Guise, T. A. and Massague, J. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3, 537-549.   DOI   ScienceOn
98 Theriault, B. L., Shepherd, T. G., Mujoomdar, M. L. and Nachtigal, M. W. (2007) BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis. 28, 1153-1162.   DOI   ScienceOn
99 Feeley, B. T., Krenek, L., Liu, N., Hsu, W. K., Gamradt, S. C., Schwarz, E. M., Huard, J. and Lieberman, J. R. (2006) Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38, 154-166.   DOI   ScienceOn
100 Katsuno, Y., Hanyu, A., Kanda, H., Ishikawa, Y., Akiyama, F., Iwase, T., Ogata, E., Ehata, S., Miyazono, K. and Imamura, T. (2008) Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27, 6322-6333.   DOI   ScienceOn
101 Moreau, J. E., Anderson, K., Mauney, J. R., Nguyen, T., Kaplan, D. L. and Rosenblatt, M. (2007) Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res. 67, 10304-10308.   DOI   ScienceOn
102 Deng, H., Ravikumar, T. S. and Yang, W. L. (2007) Bone morphogenetic protein-4 inhibits heat-induced apoptosis by modulating MAPK pathways in human colon cancer HCT116 cells. Cancer Lett. 256, 207-217.   DOI   ScienceOn
103 Bottcher, Y., Unbehauen, H., Kloting, N., Ruschke, K., Korner, A., Schleinitz, D., Tonjes, A., Enigk, B., Wolf, S., Dietrich, K., Koriath, M., Scholz, G. H., Tseng, Y. H., Dietrich, A., Schon, M. R., Kiess, W., Stumvoll, M., Bluher, M. and Kovacs, P. (2009) Adipose tissue expression and genetic variants of the bone morphogenetic protein receptor 1A gene (BMPR1A) are associated with human obesity. Diabetes 58, 2119-2128.   DOI   ScienceOn
104 Chen, J. W., Christiansen, J. S. and Lauritzen, T. (2003) Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes Obes. Metab. 5, 223-233.   DOI   ScienceOn
105 Chen, W., Salojin, K. V., Mi, Q. S., Grattan, M., Meagher, T. C., Zucker, P. and Delovitch, T. L. (2004) Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type 1 diabetes. Endocrinology 145, 627-638.   DOI   ScienceOn
106 Schulz, T. J. and Tseng, Y. H. (2009) Emerging role of bone morphogenetic proteins in adipogenesis and energy metabolism. Cytokine. Growth. Factor. Rev. 20, 523-531.   DOI   ScienceOn
107 Wu, Y., Zhou, S. and Smas, C. M. (2010) Downregulated expression of the secreted glycoprotein follistatin-like 1 (Fstl1) is a robust hallmark of preadipocyte to adipocyte conversion. Mech. Dev. 127, 183-202.   DOI   ScienceOn
108 Allen, D. L., Cleary, A. S., Speaker, K. J., Lindsay, S. F., Uyenishi, J., Reed, J. M., Madden, M. C. and Mehan, R. S. (2008) Myostatin, activin receptor IIb, and follistatin- like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am. J. Physiol. Endocrinol. Metab. 294, E918-927.   DOI   ScienceOn
109 Chen, T. L., Shen, W. J. and Kraemer, F. B. (2001) Human BMP-7/OP-1 induces the growth and differentiation of adipocytes and osteoblasts in bone marrow stromal cell cultures. J. Cell Biochem. 82, 187-199.   DOI   ScienceOn
110 Kang, M. H., Kim, J. S., Seo, J. E., Oh, S. C. and Yoo, Y. A. (2010) BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp. Cell. Res. 316, 24-37.   DOI   ScienceOn
111 Orr, F. W., Sanchez-Sweatman, O. H., Kostenuik, P. and Singh, G. (1995) Tumor-bone interactions in skeletal metastasis. Clin. Orthop. Relat. Res. 312, 19-33.
112 Mundy, G. R. (1997) Mechanisms of bone metastasis. Cancer 80, 1546-1556.   DOI   ScienceOn
113 Mitchell, D., Pobre, E. G., Mulivor, A. W., Grinberg, A. V., Castonguay, R., Monnell, T. E., Solban, N., Ucran, J. A., Pearsall, R. S., Underwood, K. W., Seehra, J. and Kumar, R. (2010) ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol. Cancer. Ther. 9, 379-388.   DOI
114 Mitchell, D. C. and Bryan, B. A. (2010) Anti-angiogenic therapy: adapting strategies to overcome resistant tumors. J. Cell Biochem. 111, 543-553.   DOI   ScienceOn
115 Hay, E. D. and Zuk, A. (1995) Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am. J. Kidney. Dis. 26, 678-690.   DOI   ScienceOn
116 Klymkowsky, M. W. and Savagner, P. (2009) Epithelialmesenchymal transition: a cancer researcher's conceptual friend and foe. Am. J. Pathol. 174, 1588-1593.   DOI   ScienceOn
117 Polyak, K. and Weinberg, R. A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer. 9, 265-273.   DOI   ScienceOn
118 Thiery, J. P., Acloque, H., Huang, R. Y. and Nieto, M. A. (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.   DOI   ScienceOn
119 Richard, D., Carpentier, A. C., Dore, G., Ouellet, V. and Picard, F. (2010) Determinants of brown adipocyte development and thermogenesis. Int. J. Obes (Lond). 34 (Suppl 2), S59-66.   DOI   ScienceOn
120 Neumann, K., Endres, M., Ringe, J., Flath, B., Manz, R., Haupl, T., Sittinger, M. and Kaps, C. (2007) BMP7 promotes adipogenic but not osteo-/chondrogenic differentiation of adult human bone marrow-derived stem cells in high-density micro-mass culture. J. Cell Biochem. 102, 626-637.   DOI   ScienceOn
121 Dani, C., Smith, A. G., Dessolin, S., Leroy, P., Staccini, L., Villageois, P., Darimont, C. and Ailhaud, G. (1997) Differentiation of embryonic stem cells into adipocytes in vitro. J. Cell. Sci. 110(Pt 11), 1279-1285.
122 Bowers, R. R. and Lane, M. D. (2007) A role for bone morphogenetic protein-4 in adipocyte development. Cell Cycle. 6, 385-389.   DOI
123 Ji, X., Chen, D., Xu, C., Harris, S. E., Mundy, G. R. and Yoneda, T. (2000) Patterns of gene expression associated with BMP-2-induced osteoblast and adipocyte differentiation of mesenchymal progenitor cell 3T3-F442A. J. Bone Miner. Metab. 18, 132-139.   DOI
124 Sottile, V. and Seuwen, K. (2000) Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone). FEBS Lett. 475, 201-204.   DOI   ScienceOn
125 Hata, K., Nishimura, R., Ikeda, F., Yamashita, K., Matsubara, T., Nokubi, T. and Yoneda, T. (2003) Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis. Mol. Biol. Cell 14, 545-555.   DOI   ScienceOn
126 Jin, W., Takagi, T., Kanesashi, S. N., Kurahashi, T., Nomura, T., Harada, J. and Ishii, S. (2006) Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad proteins. Dev. Cell 10, 461-471.   DOI   ScienceOn
127 Ma, L., Lu, M. F., Schwartz, R. J. and Martin, J. F. (2005) Bmp2 is essential for cardiac cushion epithelial-mesenchymal transition and myocardial patterning. Development 132, 5601-5611.   DOI   ScienceOn
128 Yilmaz, M. and Christofori, G. (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer. Metastasis. Rev. 28, 15-33.   DOI
129 Barrallo-Gimeno, A. and Nieto, M. A. (2005) The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132, 3151-3161.   DOI   ScienceOn
130 Sethi, N. and Kang, Y. (2011) Dysregulation of developmental pathways in bone metastasis. Bone 48, 16-22.   DOI   ScienceOn
131 Smadja, D. M., Bieche, I., Silvestre, J. S., Germain, S., Cornet, A., Laurendeau, I., Duong-Van-Huyen, J. P., Emmerich, J., Vidaud, M., Aiach, M. and Gaussem, P. (2008) Bone morphogenetic proteins 2 and 4 are selectively expressed by late outgrowth endothelial progenitor cells and promote neoangiogenesis. Arterioscler. Thromb. Vasc. Biol. 28, 2137-2143.   DOI   ScienceOn
132 Bieniasz, M., Oszajca, K., Eusebio, M., Kordiak, J., Bartkowiak, J. and Szemraj, J. (2009) The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer 66, 319-326.   DOI   ScienceOn
133 Moreno-Miralles, I., Schisler, J. C. and Patterson, C. (2009) New insights into bone morphogenetic protein signaling: focus on angiogenesis. Curr. Opin. Hematol. 16, 195-201.   DOI   ScienceOn
134 Nimmagadda, S., Geetha Loganathan, P., Huang, R., Scaal, M., Schmidt, C. and Christ, B. (2005) BMP4 and noggin control embryonic blood vessel formation by antagonistic regulation of VEGFR-2 (Quek1) expression. Dev. Biol. 280, 100-110.   DOI   ScienceOn
135 Colman, E. (2005) Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann. Intern. Med. 143, 380-385.   DOI   ScienceOn
136 Chen, D., Ji, X., Harris, M. A., Feng, J. Q., Karsenty, G., Celeste, A. J., Rosen, V., Mundy, G. R. and Harris, S. E. (1998) Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J. Cell. Biol. 142, 295-305.   DOI
137 Sebald, W., Nickel, J., Zhang, J. L. and Mueller, T. D. (2004) Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol. Chem. 385, 697-710.   DOI   ScienceOn
138 Snow, V., Barry, P., Fitterman, N., Qaseem, A. and Weiss, K. (2005) Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 142, 525-531.   DOI   ScienceOn
139 Gesta, S., Tseng, Y. H. and Kahn, C. R. (2007) Developmental origin of fat: tracking obesity to its source. Cell 131, 242-256.   DOI   ScienceOn
140 Martinsson, A. (1969) Hypertrophy and hyperplasia of human adipose tissue in obesity. Pol. Arch. Med. Wewn. 42, 481-486.
141 Shepherd, P. R., Gnudi, L., Tozzo, E., Yang, H., Leach, F. and Kahn, B. B. (1993) Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J. Biol. Chem. 268, 22243-22246.
142 Otto, T. C. and Lane, M. D. (2005) Adipose development: from stem cell to adipocyte. Crit. Rev. Biochem. Mol. Biol. 40, 229-242.   DOI   ScienceOn
143 Tang, Q. Q., Otto, T. C. and Lane, M. D. (2004) Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc. Natl. Acad. Sci. U.S.A. 101, 9607-9611.   DOI   ScienceOn
144 Bergers, G. and Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410.   DOI   ScienceOn
145 Scharpfenecker, M., van Dinther, M., Liu, Z., van Bezooijen, R. L., Zhao, Q., Pukac, L., Lowik, C. W. and ten Dijke, P. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGFstimulated angiogenesis. J. Cell. Sci. 120, 964-972.   DOI   ScienceOn
146 David, L., Mallet, C., Keramidas, M., Lamande, N., Gasc, J. M., Dupuis-Girod, S., Plauchu, H., Feige, J. J. and Bailly, S. (2008) Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res. 102, 914-922.   DOI   ScienceOn
147 Liu, Z., Kobayashi, K., van Dinther, M., van Heiningen, S. H., Valdimarsdottir, G., van Laar, T., Scharpfenecker, M., Lowik, C. W., Goumans, M. J., Ten Dijke, P. and Pardali, E. (2009) VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression. J. Cell. Sci. 122, 3294-3302.   DOI   ScienceOn
148 Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature 438, 932-936.   DOI   ScienceOn
149 Carmeliet, P. (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology (Williston Park). 69(Suppl 3), 4-10.   DOI   ScienceOn
150 David, L., Feige, J. J. and Bailly, S. (2009) Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine. Growth. Factor Rev. 20, 203-212.   DOI   ScienceOn
151 Langenfeld, E. M. and Langenfeld, J. (2004) Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol. Cancer Res. 2, 141-149.
152 Valdimarsdottir, G., Goumans, M. J., Rosendahl, A., Brugman, M., Itoh, S., Lebrin, F., Sideras, P. and ten Dijke, P. (2002) Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 106, 2263-2270.   DOI   ScienceOn
153 Reddi, A. H. (2005) BMPs: from bone morphogenetic proteins to body morphogenetic proteins. Cytokine. Growth. Factor. Rev. 16, 249-250.   DOI   ScienceOn
154 Tseng, Y. H., Kokkotou, E., Schulz, T. J., Huang, T. L., Winnay, J. N., Taniguchi, C. M., Tran, T. T., Suzuki, R., Espinoza, D. O., Yamamoto, Y., Ahrens, M. J., Dudley, A. T., Norris, A. W., Kulkarni, R. N. and Kahn, C. R. (2008) New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature. 454, 1000-1004.   DOI   ScienceOn
155 Bowers, R. R., Kim, J. W., Otto, T. C. and Lane, M. D. (2006) Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: role of the BMP-4 gene. Proc. Natl. Acad. Sci. U.S.A. 103, 13022-13027.   DOI   ScienceOn
156 Wagner, D. O., Sieber, C., Bhushan, R., Borgermann, J. H., Graf, D. and Knaus, P. (2010) BMPs: from bone to body morphogenetic proteins. Sci. Signal. 3, mr1.
157 Satterfield, M. C. and Wu, G. (2011) Brown adipose tissue growth and development: significance and nutritional regulation. Front. Biosci. 16, 1589-1608.   DOI
158 Kopelman, P. G. (2000) Obesity as a medical problem. Nature 404, 635-643.   DOI
159 Hsu, I. R., Kim, S. P., Kabir, M. and Bergman, R. N. (2007) Metabolic syndrome, hyperinsulinemia, and cancer. Am J. Clin. Nutr. 86, s867-871.   DOI
160 Craft, S. (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer. Res. 4, 147-152.   DOI   ScienceOn
161 Herrera, B., van Dinther, M., Ten Dijke, P. and Inman, G. J. (2009) Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 69, 9254-9262.   DOI   ScienceOn
162 Raida, M., Clement, J. H., Leek, R. D., Ameri, K., Bicknell, R., Niederwieser, D. and Harris, A. L. (2005) Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J. Cancer Res. Clin. Oncol. 131, 741-750.   DOI
163 Peng, H., Usas, A., Olshanski, A., Ho, A. M., Gearhart, B., Cooper, G. M. and Huard, J. (2005) VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. J. Bone Miner. Res. 20, 2017-2027.   DOI   ScienceOn
164 Rothhammer, T., Bataille, F., Spruss, T., Eissner, G. and Bosserhoff, A. K. (2007) Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 26, 4158-4170.   DOI   ScienceOn
165 Alarmo, E. L., Parssinen, J., Ketolainen, J. M., Savinainen, K., Karhu, R. and Kallioniemi, A. (2009) BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett. 275, 35-43.   DOI   ScienceOn
166 Arnold, S. F., Tims, E. and McGrath, B. E. (1999) Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2. Cytokine. 11, 1031-1037.   DOI   ScienceOn
167 Ro, T. B., Holt, R. U., Brenne, A. T., Hjorth-Hansen, H., Waage, A., Hjertner, O., Sundan, A. and Borset, M. (2004) Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23, 3024-3032.   DOI   ScienceOn
168 Piccirillo, S. G., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H., Olivi, A., Dimeco, F. and Vescovi, A. L. (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour- initiating cells. Nature 444, 761-765.   DOI   ScienceOn
169 Hammond, R. A. and Levine, R. (2010) The economic impact of obesity in the United States. Diabetes. Metab. Syndr. Obes. 3, 285-295.   DOI
170 Cornier, M. A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H. and Eckel, R. H. (2008) The metabolic syndrome. Endocr. Rev. 29, 777-822.   DOI   ScienceOn
171 Zamani, N. and Brown, C. W. (2011) Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure. Endocr. Rev. 32, 387-403.   DOI   ScienceOn
172 Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.   DOI   ScienceOn
173 Du, J., Yang, S., Wang, Z., Zhai, C., Yuan, W., Lei, R., Zhang, J. and Zhu, T. (2008) Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways. J. Cell. Biochem. 103, 1584-1597.   DOI   ScienceOn
174 Johnsen, I. K., Kappler, R., Auernhammer, C. J. and Beuschlein, F. (2009) Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis. Cancer Res. 69, 5784-5792.   DOI   ScienceOn
175 Quan, G. M. and Choong, P. F. (2006) Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev. 25, 707-713.
176 Reynolds, P. N. (2011) Gene therapy for pulmonary hypertension: prospects and challenges. Expert. Opin. Biol. Ther. 11, 133-143.   DOI   ScienceOn
177 Reynolds, P. N. (2011) Viruses in pharmaceutical research: pulmonary vascular disease. Mol. Pharm. 8, 56-64.   DOI   ScienceOn
178 Yuan, J. X. and Rubin, L. J. (2005) Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 111, 534-538.   DOI   ScienceOn
179 Baliga, R. S., MacAllister, R. J. and Hobbs, A. J. (2011) New perspectives for the treatment of pulmonary hypertension. Br. J. Pharmacol. 163, 125-140.   DOI   ScienceOn
180 Pardali, E. and ten Dijke, P. (2009) Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci. 14, 4848-4861.   DOI
181 Massague, J. (2008) TGFbeta in Cancer. Cell 134, 215-230.   DOI   ScienceOn
182 Kleeff, J., Maruyama, H., Ishiwata, T., Sawhney, H., Friess, H., Buchler, M. W. and Korc, M. (1999) Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 116, 1202-1216.   DOI   ScienceOn
183 Singh, A. and Morris, R. J. (2010) The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine. Growth. Factor. Rev. 21, 299-313.   DOI   ScienceOn
184 Wharton, K. and Derynck, R. (2009) TGFbeta family signaling: novel insights in development and disease. Development 136, 3691-3697.   DOI   ScienceOn
185 Walsh, D. W., Godson, C., Brazil, D. P. and Martin, F. (2010) Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends. Cell Biol. 20, 244-256.   DOI   ScienceOn
186 Humbert, M., Deng, Z., Simonneau, G., Barst, R. J., Sitbon, O., Wolf, M., Cuervo, N., Moore, K. J., Hodge, S. E., Knowles, J. A. and Morse, J. H. (2002) BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur. Respir. J. 20, 518-523.   DOI   ScienceOn
187 Lowery, J. W., Frump, A. L., Anderson, L., DiCarlo, G. E., Jones, M. T. and de Caestecker, M. P. (2010) ID family protein expression and regulation in hypoxic pulmonary hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299, R1463-1477.   DOI   ScienceOn
188 Foletta, V. C., Lim, M. A., Soosairajah, J., Kelly, A. P., Stanley, E. G., Shannon, M., He, W., Das, S., Massague, J. and Bernard, O. (2003) Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J. Cell. Biol. 162, 1089-1098.   DOI   ScienceOn
189 Frank, D. B., Lowery, J., Anderson, L., Brink, M., Reese, J. and de Caestecker, M. (2008) Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. Am. J. Physiol. Lung. Cell. Mol. Physiol. 294, L98-109.   DOI
190 Hong, K. H., Lee, Y. J., Lee, E., Park, S. O., Han, C., Beppu, H., Li, E., Raizada, M. K., Bloch, K. D. and Oh, S. P. (2008) Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation. 118, 722-730.   DOI   ScienceOn
191 Song, Y., Coleman, L., Shi, J., Beppu, H., Sato, K., Walsh, K., Loscalzo, J. and Zhang, Y. Y. (2008) Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am. J. Physiol. Heart Circ. Physiol. 295, H677-690.   DOI   ScienceOn
192 Song, Y., Jones, J. E., Beppu, H., Keaney, J. F., Jr., Loscalzo, J. and Zhang, Y. Y. (2005) Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 112, 553-562.   DOI   ScienceOn
193 West, J. (2010) Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension. Adv. Exp. Med. Biol. 661, 265-278.   DOI   ScienceOn
194 Cruikshank, R. P. and Chern, B. W. (2011) Bevacizumab and hereditary haemorrhagic telangiectasia. Med. J. Aust. 194, 324-325.
195 Machado, R. D., Eickelberg, O., Elliott, C. G., Geraci, M. W., Hanaoka, M., Loyd, J. E., Newman, J. H., Phillips, J. A., 3rd, Soubrier, F., Trembath, R. C. and Chung, W. K. (2009) Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54, S32-42.   DOI   ScienceOn
196 Lane, K. B., Machado, R. D., Pauciulo, M. W., Thomson, J. R., Phillips, J. A., 3rd, Loyd, J. E., Nichols, W. C. and Trembath, R. C. (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat. Genet. 26, 81-84.   DOI   ScienceOn
197 Atkinson, C., Stewart, S., Upton, P. D., Machado, R., Thomson, J. R., Trembath, R. C. and Morrell, N. W. (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672-1678.   DOI
198 Thomson, J. R., Machado, R. D., Pauciulo, M. W., Morgan, N. V., Humbert, M., Elliott, G. C., Ward, K., Yacoub, M., Mikhail, G., Rogers, P., Newman, J., Wheeler, L., Higenbottam, T., Gibbs, J. S., Egan, J., Crozier, A., Peacock, A., Allcock, R., Corris, P., Loyd, J. E., Trembath, R. C. and Nichols, W. C. (2000) Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J. Med. Genet. 37, 741-745.   DOI
199 Simonneau, G., Galie, N., Rubin, L. J., Langleben, D., Seeger, W., Domenighetti, G., Gibbs, S., Lebrec, D., Speich, R., Beghetti, M., Rich, S. and Fishman, A. (2004) Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43, S5-12.   DOI   ScienceOn
200 Du, L., Sullivan, C. C., Chu, D., Cho, A. J., Kido, M., Wolf, P. L., Yuan, J. X., Deutsch, R., Jamieson, S. W. and Thistlethwaite, P. A. (2003) Signaling molecules in nonfamilial pulmonary hypertension. N. Engl. J. Med. 348, 500-509.   DOI   ScienceOn
201 Arthur, H. M., Ure, J., Smith, A. J., Renforth, G., Wilson, D. I., Torsney, E., Charlton, R., Parums, D. V., Jowett, T., Marchuk, D. A., Burn, J. and Diamond, A. G. (2000) Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol. 217, 42-53.   DOI   ScienceOn
202 Srinivasan, S., Hanes, M. A., Dickens, T., Porteous, M. E., Oh, S. P., Hale, L. P. and Marchuk, D. A. (2003) A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum. Mol. Genet. 12, 473-482.   DOI   ScienceOn
203 Park, S. O., Lee, Y. J., Seki, T., Hong, K. H., Fliess, N., Jiang, Z., Park, A., Wu, X., Kaartinen, V., Roman, B. L. and Oh, S. P. (2008) ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 111, 633-642.   DOI   ScienceOn
204 Machado, R. D., Aldred, M. A., James, V., Harrison, R. E., Patel, B., Schwalbe, E. C., Gruenig, E., Janssen, B., Koehler, R., Seeger, W., Eickelberg, O., Olschewski, H., Elliott, C. G., Glissmeyer, E., Carlquist, J., Kim, M., Torbicki, A., Fijalkowska, A., Szewczyk, G., Parma, J., Abramowicz, M. J., Galie, N., Morisaki, H., Kyotani, S., Nakanishi, N., Morisaki, T., Humbert, M., Simonneau, G., Sitbon, O., Soubrier, F., Coulet, F., Morrell, N. W. and Trembath, R. C. (2006) Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat. 27, 121-132.   DOI   ScienceOn
205 Bergeron, E., Marquis, M. E., Chretien, I. and Faucheux, N. (2007) Differentiation of preosteoblasts using a delivery system with BMPs and bioactive glass microspheres. J. Mater. Sci. Mater. Med. 18, 255-263.   DOI   ScienceOn
206 Geiger, M., Li, R. H. and Friess, W. (2003) Collagen sponges for bone regeneration with rhBMP-2. Adv. Drug. Deliv. Rev. 55, 1613-1629.   DOI   ScienceOn
207 Bourdeau, A., Faughnan, M. E. and Letarte, M. (2000) Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends. Cardiovasc. Med. 10, 279-285.   DOI   ScienceOn
208 Bourdeau, A., Cymerman, U., Paquet, M. E., Meschino, W., McKinnon, W. C., Guttmacher, A. E., Becker, L. and Letarte, M. (2000) Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am. J. Pathol. 156, 911-923.   DOI   ScienceOn
209 Mitchell, A., Adams, L. A., MacQuillan, G., Tibballs, J., vanden Driesen, R. and Delriviere, L. (2008) Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver. Transpl. 14, 210-213.   DOI   ScienceOn
210 Johnson, D. W., Berg, J. N., Baldwin, M. A., Gallione, C. J., Marondel, I., Yoon, S. J., Stenzel, T. T., Speer, M., Pericak-Vance, M. A., Diamond, A., Guttmacher, A. E., Jackson, C. E., Attisano, L., Kucherlapati, R., Porteous, M. E. and Marchuk, D. A. (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet. 13, 189-195.   DOI   ScienceOn
211 Gallione, C. J., Richards, J. A., Letteboer, T. G., Rushlow, D., Prigoda, N. L., Leedom, T. P., Ganguly, A., Castells, A., Ploos van Amstel, J. K., Westermann, C. J., Pyeritz, R. E. and Marchuk, D. A. (2006) SMAD4 mutations found in unselected HHT patients. J. Med. Genet. 43, 793-797.   DOI